Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
41 hedge funds and large institutions have $46.3M invested in Cyteir Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
11% more capital invested
Capital invested by funds: $41.7M → $46.3M (+$4.67M)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
5% more funds holding
Funds holding: 39 → 41 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$3.15M |
| 2 |
VAS
VR Advisory Services
Camana Bay, Grand Cayman,
Cayman Islands
|
+$2.96M |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
+$1.22M |
| 4 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
+$1.15M |
| 5 |
Walleye Capital
New York
|
+$975K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$8.23M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$1.36M |
| 3 |
VAM
Vazirani Asset Management
New York
|
-$387K |
| 4 |
EWM
Evercore Wealth Management
New York
|
-$381K |
| 5 |
Renaissance Technologies
New York
|
-$96.8K |
CYT Hedge Fund Activity: Q3 2023 in Review
41 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q3 2023, worth a combined $46.3M — up 11% from $41.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CYT positions and 9 closed out — a net gain of 2 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Newtyn Management, adding an estimated $3.15M. The largest seller was Novo Holdings A/S, cutting an estimated $8.23M.
- 41 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q3 2023, up from 39 in Q2 2023.
- Funds reported $46.3M of Cyteir Therapeutics, Inc. Common Stock stock for Q3 2023, up 11% quarter-over-quarter.
- 11 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q3 2023 and 9 closed out, a net change of +2 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q3 2023 was Newtyn Management, an estimated $3.15M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q3 2023 was Novo Holdings A/S, an estimated $8.23M sold.
Based on aggregated 13F filings for Q3 2023.